Upon receiving bevacizumab treatment, the glycolysis in hypoxic cancer cells may be further enhanced, subsequently leading to increased levels of histone lactylation and the transcriptional upregulation of RUBCNL through lactylation, which contributes to the survival of colorectal cancer cells and resistance to treatment. The gene discussed is RUBCNL; the disease is colorectal cancer.